This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

7 Mar 2012

Medicago Forms Alliance with Mitsubishi Tanabe Pharma for Rotavirus Vaccines Development

Canada's Medicago and Osaka-based Mitsubishi Tanabe Pharma have formed a strategic alliance to develop three new rotavirus vaccines.

Canadian biopharmaceutical firm Medicago announced Tuesday that the company has established a strategic alliance with Japanese drug company Mitsubishi Tanabe Pharma Corporation (MTPC) to develop three new rotavirus vaccines.


Medicago will develop and market the first vaccine to prevent rotavirus infection in children and Mitsubishi will fund all research and development costs.


Medicago will receive an upfront payment of C$3m to begin the initial research and will also be eligible to receive up to a total of C$33m in milestones and royalty payments on future sales of the rotavirus product.


Work on a Rotavirus Like Particle (RLP) vaccine target will begin immediately. Further targets under t

Related News